• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Roth Capital Upgraded Zynerba to a Buy Rating

August 16, 2017


Michael Higgins, the Senior Research Analyst for Specialty Pharmaceuticals at ROTH Capital Partners upgraded shares of Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) from a Neutral rating to Buy rating. Higgins' new price target for the stock is $15 per share. At the time of writing this, shares of ZYNE were trading at $6.91 per share, representing a roughly 117% upside. 


Related: ZYNE Shares Plunge 50% on Clinical Trial Data


Higgins' $15 price target is just north of the average analyst price target of $14.38, according to Yahoo Finance. As reported by StreetInsider, "Michael Higgins sees an opportunity to get long after telling clients that he was previously bullish on the ZYN002 trial." Higgins' upgrade comes the same day that Oppenheimer downgraded Zynerba from Outperform to Market Perform and Jefferies downgraded Zynerba from a Buy to a Hold.


Related: 7 Things to Know About ZYNE's Pipeline & Q2 Earnings


For more cannabinoid biotech stocks, check out our biotech marijuana stock database. Be sure to subscribe to one or more of our free newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram



Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.